蛋白酪氨酸磷酸酶非受体型22基因R620W多态性与重症肌无力风险相关：一项系统评价和荟萃分析

PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysis.

作者信息

Xiong Xunbo, Xiang Mingqing, Cheng Xianglin, Huang Yi

机构信息

Department of Neurology, The First Hospital of Yangtze University, Jingzhou, Hubei, China (mainland).

出版信息

Med Sci Monit. 2015 Aug 30;21:2567-71. doi: 10.12659/MSM.894307.

DOI:10.12659/MSM.894307

PMID:26318187

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4559008/

Abstract

BACKGROUND

The association between PTPN22 R620W polymorphism and risk of myasthenia gravis (MG) remains controversial. Therefore, we did this meta-analysis to investigate this association.

MATERIAL AND METHODS

We did a comprehensive search in PubMed, Medline, Embase, CNKI (China National Knowledge Infrastructure), and Wanfang electronic databases to retrieve relevant articles. The overall effect was measured by odds ratios (ORs) with its 95% confidence intervals (CIs). Statistical analyses were conducted with STATA software.

RESULTS

Overall, a total of 7 case-control studies with 2802 cases and 3730 controls were finally included in this review. PTPN22 R620W polymorphism was significantly associated with an increased risk of MG (OR=1.57; 95% CI, 1.34-1.82; I(2)=31%). In the subgroup analysis, thymoma patients were significantly associated with risk of MG (OR=1.59; 95% CI, 1.28-1.98; I(2)=0%). However, non-thymoma patients with this polymorphism did not have increased MG risk (OR=1.36; 95% CI, 0.86-2.15; I(2)=77%). In addition, PTPN22 R620W polymorphism showed increased early-onset myasthenia gravis (EOMG) risk (OR=2.38; 95% CI, 1.52-3.71; I(2)=0%).

CONCLUSIONS

This meta-analysis shows a significant association between PTPN22 R620W polymorphism and MG risk.

摘要

背景

蛋白酪氨酸磷酸酶非受体型22（PTPN22）基因R620W多态性与重症肌无力（MG）风险之间的关联仍存在争议。因此，我们进行了这项荟萃分析以研究这种关联。

材料与方法

我们全面检索了PubMed、Medline、Embase、中国知网（CNKI）和万方电子数据库，以获取相关文章。总体效应通过比值比（OR）及其95%置信区间（CI）来衡量。使用STATA软件进行统计分析。

结果

总体而言，本综述最终纳入了7项病例对照研究，共2802例病例和3730例对照。PTPN22 R620W多态性与MG风险增加显著相关（OR = 1.57；95%CI，1.34 - 1.82；I² = 31%）。在亚组分析中，胸腺瘤患者与MG风险显著相关（OR = 1.59；95%CI，1.28 - 1.98；I² = 0%）。然而，具有这种多态性的非胸腺瘤患者MG风险并未增加（OR = 1.36；95%CI，0.86 - 2.15；I² = 77%）。此外，PTPN22 R620W多态性显示早发型重症肌无力（EOMG）风险增加（OR = 2.38；95%CI，1.52 - 3.71；I² = 0%）。